Early observations and pilot data that first suggested a new direction
ACR 2020 strongly recommends allopurinol as preferred first-line urate-lowering therapy, with dose titration guided by serial serum urate to a target <6 mg/dL. CARES randomized 6,190 patients with gout and cardiovascular disease. Febuxostat was noninferior to allopurinol for its cardiovascular composite (HR 1.03; one-sided 98.5% CI upper limit 1.23; p=0.002 for noninferiority). All-cause mortality was higher (HR 1.22; 95% CI 1.01–1.47), as was cardiovascular mortality (HR 1.34; 95% CI 1.03–1.73). Median follow-up was 32 months; treatment and follow-up discontinuation were substantial.
Landmark RCTs and pivotal trials that established the evidence base
FAST randomized 6,128 patients already receiving allopurinol and with an additional cardiovascular risk factor. Febuxostat was noninferior to allopurinol for the primary cardiovascular endpoint in the on-treatment analysis (adjusted HR 0.85; 95% CI 0.70–1.03). Death occurred in 7.2% assigned febuxostat versus 8.6% assigned allopurinol. Unlike CARES, FAST did not identify an increased risk of death with febuxostat. Its exclusions included recent myocardial infarction or stroke, severe heart failure, and severe renal impairment.
Follow-up studies, subgroup analyses, and real-world validation
CARES and FAST studied different populations and produced different mortality findings. In CARES, 56.6% discontinued treatment and 45.0% discontinued follow-up. Mortality results during treatment were similar to the modified intention-to-treat results. FAST excluded some higher-risk groups and did not find increased mortality with febuxostat. Separately, a randomized nurse-led gout care trial found that education, engagement, and treat-to-target ULT improved serum urate target attainment at 2 years.
Integration into clinical practice guidelines and recommendations
ACR 2020 strongly recommends allopurinol first-line for patients starting ULT and titration to serum urate <6 mg/dL. For prior allopurinol allergy when other oral ULT cannot be used, it conditionally recommends desensitization. The 2016 EULAR update (published 2017) recommends allopurinol first-line; if the urate target is not achieved, consider febuxostat, a uricosuric or combination therapy.
ACR
Allopurinol first-line; SU <6 mg/dL; prior allopurinol allergy with no other oral ULT option: desensitization (conditional).
Allopurinol first-line; SUA <6 mg/dL; consider febuxostat or a uricosuric if target is not achieved.
Now
Current standard of care and ongoing research directions
ACR 2020 recommends allopurinol first-line and titration to serum urate <6 mg/dL. CARES and FAST reported different febuxostat mortality findings in different populations. FAST enrolled patients aged 60 or older already taking allopurinol and excluded recent myocardial infarction/stroke, severe heart failure and severe renal impairment. It found noninferiority for its on-treatment cardiovascular endpoint without increased mortality. These results require attention to eligibility and analysis rather than assuming that one trial cancels the other.
CARES found higher all-cause mortality with febuxostat versus allopurinol (HR 1.22) in patients with gout and cardiovascular disease. FAST found noninferiority for its cardiovascular endpoint (adjusted HR 0.85); deaths occurred in 7.2% versus 8.6%. The populations and trial methods differed. These findings require attention to patient selection rather than assuming that one trial cancels the other.
What is the treat-to-target approach in gout?+
The ACR 2020 guideline recommends a low starting allopurinol dose of ≤100 mg/day, lower in CKD, followed by titration guided by serial serum urate measurements to a target below 6 mg/dL. Anti-inflammatory prophylaxis for at least 3–6 months is strongly recommended when ULT starts.